Renergen Limited and ASP Isotopes Inc. have provided an update on the progress towards implementing their Scheme of Arrangement. The companies have received key milestone transaction approvals, including the approval from the Competition Commission, paving the way for integration processes and collaboration. The written consent to the transfer of Renergen Shares in terms of the Offer has been obtained from the Industrial Development Corporation of South Africa and the United States International Development Finance Corporation, fulfilling a relevant Offer Condition.
The deadline for the fulfillment of the remaining Conditions has been extended proactively to January 30, 2026. The parties remain confident that the remaining Conditions will be fulfilled (or, where applicable, waived) in due course and are engaged in working together to obtain the required approvals as quickly as possible. Once the remaining Conditions have been fulfilled (or waived), the updated salient dates and times for the Scheme will be announced on SENS and on the ASX.
In terms of the ASPI Funding Arrangements, the date for Renergen’s repayment of the funding advanced to it has been extended to January 30, 2026, by agreement between the parties.
The Independent Board of Renergen and the board of directors of ASPI have accepted responsibility for the information contained in the announcement and confirm its accuracy.
The press release was issued on November 27, 2025, and PSG Capital is serving as the Transaction and Designated Advisor to Renergen, while Valeo Capital is the Corporate Advisor and Sponsor to ASPI. As a result of these announcements, the company's shares have moved 5.07% on the market, and are now trading at a price of $6.22. Check out the company's full 8-K submission here.
